Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05896826

Magnetocardiography in the Accurate Identification of Myocardial Infarction

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial infarction. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography). Myocardial infarction is also quantified by cardiac magnetic resonance or single-photon-emission tomography. Healthy volunteers and chest pain patients who will receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography) examination will be enrolled in this study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

Location status: Recruiting

Location contact

Jiaojiao Pang, Doctor

CONTACT

[email protected]

0086-0531-82165398

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

For healthy volunteers:

Inclusion criteria

  • Age 18-79 years old;
  • No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;
  • The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).
  • Sign the informed consent.

Exclusion criteria

  • Those who with acute or chronic respiratory diseases;
  • Those who with obvious abnormality of liver or kidney function;
  • Those who with endocrine diseases such as abnormal thyroid function;
  • Those who with anemia or other blood diseases;
  • Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.);
  • Those who are obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
  • Those who with malignant tumors;
  • Those who with infectious diseases or infectious diseases;
  • Those who with trauma or physical disability;
  • Those who with psychological or mental illness such as depression;
  • Those who are professional athletes, pregnant or breastfeeding women, alcoholics;
  • Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;
  • Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.

For chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination:

Inclusion criteria

  • Age 18-79 years old;
  • Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography);
  • Sign the informed consent.

Exclusion criteria

  • Patients with known structural heart disease such as cardiomyopathy and valvular disease;
  • Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
  • History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
  • Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
  • Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
  • Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
  • Patients with malignant tumors;
  • Professional athletes, pregnant or breastfeeding women, alcoholics;
  • Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
  • Patients with infectious diseases or infectious diseases;
  • Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
  • Unable to or fail to cooperate with the corresponding research requirements.

Treatment and study plan

Magnetometer

Device

inspection equipment for magnetocardiography

Primary outcomes

  1. Accuracy of MCG to detect myocardial infarction

    Time frame: 6 hours

    To establish an algorithm model of MCG in detecting myocardial infarction and to assess the sensitivity and specificity of the above model in detecting myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography).

Secondary outcomes

  1. Accuracy of MCG to detect the localization of myocardial infarct

    Time frame: 6 hours

    To build up an algorithm model of MCG in detecting the localization of myocardial infarct. The sensitivity and specificity of the model in detecting infarct location were evaluated.

  2. Accuracy of MCG in identifying myocardial infarct sizes

    Time frame: 6 hours

    To establish an algorithm model of MCG in detecting identifying myocardial infarct sizes and to assess the sensitivity and specificity of the above model in identifying myocardial infarct sizes. Myocardial infarction sizes is quantified by cardiac magnetic resonance or single-photon-emission tomography.

Study contacts

Contact information is provided by the study sponsor or research team.

Jiaojiao Pang, Dr.

CONTACT

[email protected]

0086-0531-82165674

Sponsors and collaborators

Lead sponsor

Qilu Hospital of Shandong University

Other

Collaborators

  • Chongqing Emergency Medical Center
  • First Affiliated Hospital Xi'an Jiaotong University
  • First People's Hospital of Hangzhou
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Heze Municipal Hospital
  • Jining First People's Hospital
  • Linyi People's Hospital
  • Qianfoshan Hospital
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • The First Affiliated Hospital with Nanjing Medical University
  • Weifang People's Hospital
  • Weihai Central Hospital

Registry information

Official study title

Ultra-sensitive Magnetocardiography in the Accurate Identification of Myocardial Infarction

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Jun 9, 2023
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.